J.P. Morgan increased its holdings in INNOVENT BIO (01801) by 58,590 shares, with an approximate price per share of about HK$79.23.
On February 6th, J.P. Morgan increased its holdings in Sino Biopharmaceutical (01801) by 585,900 shares, with a price per share of HK$79.232, for a total amount of approximately HK$46.422 million.
According to the latest data from the Hong Kong Stock Exchange, on February 6th, J.P. Morgan increased its holdings of INNOVENT BIO (01801) by 585,900 shares, with an average price of HKD 79.232 per share, totaling approximately HKD 46.42 million. After the increase, the latest number of shares held is approximately 87.2176 million, with a new shareholding ratio of 5.02%.
Related Articles
Shenwan Hongyuan Group (06806) successfully issued 4 billion yuan in corporate bonds.
CSPC Innovation Pharmaceutical (300765.SZ) subsidiary SYS6023 antibody-drug conjugate obtains approval for clinical trials.
SINOPEC KANTONS (00934) signs exclusive operating agreement with Caofeidian Port Group.
Shenwan Hongyuan Group (06806) successfully issued 4 billion yuan in corporate bonds.
CSPC Innovation Pharmaceutical (300765.SZ) subsidiary SYS6023 antibody-drug conjugate obtains approval for clinical trials.
SINOPEC KANTONS (00934) signs exclusive operating agreement with Caofeidian Port Group.
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
